acyclovir has been researched along with Colonic-Neoplasms* in 5 studies
5 other study(ies) available for acyclovir and Colonic-Neoplasms
Article | Year |
---|---|
Clinical problem-solving. A creeping suspicion.
Topics: Acyclovir; Antiviral Agents; Aphasia; Cerebrospinal Fluid; Colonic Neoplasms; Diagnosis, Differential; Encephalitis, Herpes Simplex; Female; Fever; Humans; Magnetic Resonance Imaging; Middle Aged; Polymerase Chain Reaction; Simplexvirus; Spinal Puncture; Temporal Lobe | 2014 |
Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient.
Studies were conducted to investigate changes in the extent of human herpesvirus 8 (HHV-8) shedding and diversity of HHV-8 strains in the mouth of a renal allograft recipient who developed cutaneous post-transplantation Kaposi's sarcoma.. Matched oral and blood samples were obtained from a Saudi Arabian renal allograft recipient from 3 days before to 38 weeks after transplantation, and from his kidney donor. Polymerase chain reaction (PCR) protocols to amplify selected HHV-8 sub-genomic regions were applied to detect and quantify HHV-8 DNA. Sequence diversity was determined by cloning the PCR products and subjecting them to denaturing gradient gel electrophoresis and to nucleotide sequencing.. Before transplantation, the recipient was seropositive for anti-HHV-8 immunoglobulin G, but the donor was seronegative; HHV-8 DNA could be detected in the recipient's blood, whole-mouth saliva (WMS) and buccal exfoliates, and the salivary viral load was estimated as 2.6 million genome-copies/ml. Post-transplantation, the recipient's salivary viral load initially increased to 4.1 million genome-copies/ml, and thereafter declined precipitously, coinciding with an increase in the dosage of valaciclovir given; HHV-8 DNA was detected most often in WMS compared with parotid saliva, and buccal and palatal exfoliates. Carriage of multiple HHV-8 strains was evident in blood and oral samples; whereas before transplantation strains belonging to genotypes A1 and A5 were observed, after transplantation genotype A5 strains became dominant and A2 strains emerged.. Immunosuppression and antiviral prophylaxis may interact to influence the spectrum of oral HHV-8 strains and the extent of post-transplantation HHV-8 shedding into the mouth. Topics: Acyclovir; Adult; Antiviral Agents; Blood; Colonic Neoplasms; DNA, Viral; Genetic Variation; Herpesvirus 8, Human; Humans; Immunophenotyping; Immunosuppression Therapy; Kidney Transplantation; Leukocytes; Male; Molecular Sequence Data; Mouth Mucosa; Saliva; Sarcoma, Kaposi; Skin Neoplasms; Stomach Neoplasms; Valacyclovir; Valine; Viral Load; Virus Shedding | 2009 |
Atypical case of Herpes simplex encephalitis.
Topics: Acyclovir; Aged; Antineoplastic Agents; Antiviral Agents; Cerebrospinal Fluid; Colonic Neoplasms; Diabetes Mellitus, Type 2; Encephalitis, Herpes Simplex; Herpesvirus 1, Human; Humans; Immunocompromised Host; Male | 2008 |
Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET.
Synthesis and preliminary biological evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)-guanine ([18F]FHBG) is reported. 9-(4-Hydroxy-3-hydroxymethylbutyl)-guanine (penciclovir) 4 was converted to 9-[N2, O-bis-(methoxytrityl)-3-(tosylmethybutyl)]guanine 7 by treatment with methoxytrityl chloride followed by tosylation. The tosylate 7 was reacted with either tetrabutylammonium fluoride or KF in the presence of kryptofix 2.2.2. to produce the 4-fluoro-N2-O-bis-(methoxytrityl) derivative 8. Removal of the methoxytrityl groups by acidic hydrolysis produced FHBG 5. Radiolabeled product [18F]FHBG was prepared by fluorination of the tosylate 7 with [18F]KF and kryptofix 2.2.2. The labeled product was isolated by HPLC purification on a reverse-phase C18 column, and eluted at 12 min with 15% acetonitrile in water at a flow rate of 2.25 mL/min. Radiochemical yield was 8.0-22.3% with an average of 12% in 7 runs (corrected for decay). Synthesis time was 90 to 100 min including HPLC purification with radiochemical purity >99%, and average specific activity of 320 mCi/micromol. In vitro studies of the compound in HT-29 colon cancer cells revealed 18.2-fold higher uptake into transduced cells compared to control in 3 h. The agent may be useful for imaging viral infection or transfected cells in gene therapy. Topics: Acyclovir; Antiviral Agents; Biological Transport; Colonic Neoplasms; Fluorine Radioisotopes; Genetic Therapy; Guanine; Humans; Indicators and Reagents; Molecular Structure; Radionuclide Imaging; Tumor Cells, Cultured; Virus Diseases | 1998 |
Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues.
To constitute the site-specific expression of the herpes simplex virus thymidine-kinase (HSV-TK) gene in tumor cells, we have assessed the promoter function of the simian virus 40 (SV40) promoter and the 5'flanking region of c-erbB-2 gene using a luciferase-expressing reporter plasmid. After the transfection of the luciferase plasmid directed by the promoter region of c-erbB-2 gene, a large amount of luciferase activity was observed in c-erbB-2-expressing cells (Colo201, MCF-7, and HEC1-A), while none was detected in cells with no expression of c-erbB-2 protein (HRA and KF cells). On the other hand, a high level of luciferase activity was detected in all tumor cell lines tested, when the transfection was performed with SV40 promoter. The repeated transfection of the liposome-conjugated HSV-TK gene regulated by the SV40 promoter or by the promoter region of c-erbB-2 gene with cultivation in 100 micrograms/ml of aciclovir for 5 days in vitro resulted in growth inhibition for all four cell lines examined or for only c-erbB-2-expressing cells in the presence of SV40 promoter or c-erbB-2 promoter, respectively. Finally, direct injection of the DNA-liposome complex into established tumors in the presence of 50 mg/kg of aciclovir led to significant tumor volume reduction in all three tumors tested when SV40 promoter was employed. However, this anti-tumor effect was noted only in c-erbB-2-positive cells (Colo201 cells) upon intratumoral injection of HSV-TK gene regulated by c-erbB-2 promoter. In the case of intratumoral gene transfer, foreign DNA was detected in only one of seven mice by polymerase chain reaction (PCR) analysis performed 7 days following injection. When PCR analysis was carried out at 14 or 21 days following injection, no DNA signal was found at all. However, DNA was detected in several normal tissues at all three times tested in the case of intravenous injection. No abnormalities were seen in histologic examinations of normal tissues or in serum biochemical parameters following DNA liposome delivery. These results suggest that the direct gene transfer of HSV-TK gene regulated by tumor-specific transcriptional units may be one of the most clinically promising of the selective genetic strategies against cancer. Topics: Acyclovir; Adenocarcinoma; Animals; Antiviral Agents; beta-Galactosidase; Colonic Neoplasms; Female; Flow Cytometry; Gene Transfer Techniques; Genes, erbB-2; Genes, Reporter; Genetic Vectors; Herpesvirus 1, Human; Humans; Liposomes; Luciferases; Mice; Mice, Nude; Promoter Regions, Genetic; Receptor, ErbB-2; Thymidine Kinase; Tissue Distribution; Transcription, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured; Viral Proteins | 1997 |